Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272900 | 0.77 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL8980426 | 0.72 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL1382755 | 0.71 | — | — | |
| SCHEMBL12778836 | 0.70 | — | — | |
| SCHEMBL1381436 | 0.67 | — | — | |
| SCHEMBL4478986 | 0.65 | — | — | |
| SCHEMBL329576 | 0.64 | — | — | |
| SCHEMBL3551592 | 0.63 | — | — | |
| SCHEMBL3170209 | 0.63 | — | — | |
| Amylene Hydrate SCHEMBL10721 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4717006-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| JP-4717005-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| EP-1687292-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-22 | — | — | EP | claimed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | claimed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | claimed |
| US-20060293385-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-12-28 | — | — | US | claimed |
| EP-1687292-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1687289-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1687265-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | claimed |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-05-04 | — | — | US | claimed |
| EP-1587906-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | claimed |
| EP-1565422-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2005051898-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | claimed |
| WO-2005051940-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | claimed |
| WO-2005051938-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | claimed |
| WO-2004063345-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2004048309-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | claimed |
| US-7897789-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2004063345-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004048309-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293385-A1 | Vitamin d receptor modulators | VDR, CYP24A1, CYP2R1 | TSHR 314/4885TDP1 4789/4885 |
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TSHR 602/4885TDP1 4642/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TSHR 387/4885TDP1 4642/4885 |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TSHR 1436/4885TDP1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.